Drugs / AAV-CHD3-R1025W Base Editor
AAV-CHD3-R1025W Base Editor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06860672 | Feb → Apr 2025 overdue | intellectual disability, specific developmental disorder | Yongguo Yu | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV-CHD3-R1025W Base Editor | “Safety, Tolerability and Preliminary Efficacy Study of a Single Intrathecal Injection of the Dual Vector AAV-CHD3-R1025W Base Editor for the Treatment of Developmental...” NCT06860672 ↗ |
| Action | Restore | “correct the mutated CHD3 gene” NCT06860672 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “dual vector adeno-associated virus (AAV) system” NCT06860672 ↗ |
| Route | Intrathecal | “intrathecal injection” NCT06860672 ↗ |